Risks of Withdrawing Antipsychotic Medications

Archives of General Psychiatry

Volumn 52, Issue 3, 1995, Pages 205-208

  Wyatt, Richard Jed ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CHRONIC DISEASE; DRUG ADMINISTRATION; DYSKINESIA; FOLLOW UP; HUMAN; PSYCHOLOGY; RECURRENT DISEASE; RISK; RISK FACTOR; SCHIZOPHRENIA; WITHDRAWAL SYNDROME;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FOLLOW-UP STUDIES; HUMAN; META-ANALYSIS; RECURRENCE; RISK FACTORS; RISK-TAKING; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0029269274     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1995.03950150037007     Document Type: Letter

References (29)

1. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52: 173–188.
2. Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, Gualtieri CT. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Press; 1992.
3. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry. 1994;51: 643–650.
4. Khot V, Wyatt RJ. Not all that moves is tardive dyskinesia. Am J Psychiatry. 1991;148: 661–666.
5. Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983;67: 339–352.
6. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia: two decades of experience. Arch Gen Psychiatry. 1982;39: 803–816.
7. Kane JM. Incidence and prevalence of tardive dyskinesia. Presented at the 150th Annual Meeting of the American Psychiatric Association; May 25, 1994; Philadelphia, Pa.
8. Crow TJ, Macmillan JF, Johnson AL, Johnstone EC. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148: 120–127.
9. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17: 325–351.
10. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Symanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992;149: 1183–1188.
11. Wyatt RJ. Antipsychotic medication and the longterm course of schizophrenia: therapeutic and theoretical implications. In: Shriqui C, Nasrallah H, eds. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press. In press.
12. Good WW, Sterling M, Holtzman WH. Termination of chlorpromazine with schizophrenic patients. Am J Psychiatry. 1958;115: 433–448.
13. Rothstein C. An evaluation of the effects of discontinuation of chlorpromazine. N Engl J Med. 1960;262: 67–69.
14. Ruskin PE, Nyman G. Discontinuation of neuroleptic medication in older, outpatient schizophrenics: a placebo-controlled, double-blind trial. J Nerv Ment Dis. 1991;179: 212–214.
15. Glovinsky D, Kirch DG, Wyatt RJ. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry. 1992;31: 968–970.
16. Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the Medical Research Council fluphenazine/placebo trial. Br J Psychiatry. 1985;146: 464–480.
17. Herz MI, Glazer W, Mirza M, Mostert M, Hafez H. Treating prodromal episodes to prevent relapse in schizophrenia. Br J Psychiatry Suppl. July 1989: 123–127.
18. Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990;147: 1138–1148.
19. Kissling W, ed. Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. New York, NY: Springer-Verlag NY Inc; 1991.
20. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE. The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull. 1992;18: 185–207.
21. Dencker SJ, Lapp M, Malm U. Do schizophrenics well-adapted in the community need neuroleptics? a depot neuroleptic withdrawal study. Acta Psychiatr Scand Suppl. 1980;279: 64–76.
22. Green Al, Faraone SV, Brown WA. Prolactin shifts after neuroleptic withdrawal. Psychiatry Res. 1990;32: 213–219.
23. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993;50: 448–455.
24. Hogarty GE, Ulrichs RF, Mussare F, Aristigueta N. Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst. 1976;37: 494–500.
25. Johnson DAW. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand. 1976;53: 298–301.
26. Johnson DAW. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry. 1979;119: 267–276.
27. Cheung HK. Schizophrenics fully remitted on neuroleptics for 3–5 years: to stop or continue drugs? Br J Psychiatry. 1981;138: 490–494.
28. Wistedt B. A depot neuroleptic withdrawal study. Acta Psychiatr Scand. 1981;64: 65–84.
29. Bellack AS, Mueser KT. Psychosocial treatment for schizophrenia. Schizophr Bull. 1993;19: 317–336.